Get started
Author

Birgitte Bjørnhart

Observed names: B Bjørnhart, B. Bjoernhart, B. Bjornhart, B. Bjørnhart, BIRGITTE BJØRNHART, Birgitte Bjornhart, Bjørnhart, Birgitte
ORCID: 0000-0002-1331-061X
Observed ORCID: 0000-0002-1331-061X
OpenAlex ID: A5089890191
Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study
2019 · Birgitte Bjørnhart, Karin H. Hansen, et al. · Acta Oncologica · 48
PDF
Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy
2021 · Mette T. Mouritzen, Andreas Carus, et al. · Cancers · 44
PDF
Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study
2022 · Mette T. Mouritzen, Karen F. Junker, et al. · Acta Oncologica · 19
PDF
Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy
2022 · Birgitte Bjørnhart, Charlotte Kristiansen, et al. · Thrombosis Research · 17
5-Year survival in Danish patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy
2023 · Birgitte Bjørnhart, Mette Thune Mouritzen, et al. · Acta Oncologica · 16
PDF
Cartilage Oligomeric Matrix Protein in Patients with Juvenile Idiopathic Arthritis: Relation to Growth and Disease Activity
2009 · BIRGITTE BJØRNHART, ANDERS JUUL, et al. · The Journal of Rheumatology · 14
PDF
Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis
2022 · Birgitte Bjørnhart, Karin Holmskov Hansen, et al. · Cancers · 12
PDF
Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis
2004 · S Gudbrandsdottir, H Bliddal, et al. · Scandinavian Journal of Rheumatology · 10
Incidence, risk factors and clinical outcome of venous thromboembolism in non-small cell lung cancer patients receiving immune checkpoint inhibition
2021 · Birgitte Bjørnhart, Karin Holmskov Hansen, et al. · Thrombosis Update · 9
PDF
Plasma TNF binding capacity in patients with juvenile idiopathic arthritis
2004 · Birgitte Bjørnhart, Pernille Svenningsen, et al. · International Immunopharmacology · 6
Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC
2026 · Rikke Andersen, Mette Syberg Jespersen, et al. · European Journal of Cancer · 2
PDF
1333P The influence of polypharmacy on outcome in real life non-small cell lung cancer (NSCLC) patients treated with immunotherapy
2020 · B. Bjoernhart, K.H. Hansen, et al. · Annals of Oncology · 2
PDF
1547P Clinical outcomes of patients with acquired resistance to checkpoint inhibitors in melanoma, renal cell carcinoma and non-small cell lung cancer
2025 · M.J. Syberg, R. Andersen, et al. · Annals of Oncology · 1
PDF
107P: Quality of life in a real-world prospective lung cancer cohort during palliative immunotherapy
2025 · I. Meklenborg, P.K. Møller, et al. · Journal of Thoracic Oncology · 1
1334P Real word experience with first-line immunotherapy in advanced non-small cell lung cancer patients in a Danish nationwide cohort
2020 · M. Mouritzen, B. Bjoernhart, et al. · Annals of Oncology · 1
EP1.04-29 Khorana Score: A Potential New Biomarker for Real Life Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Immunotherapy
2019 · B. Bjørnhart, K. Hansen, et al. · Journal of Thoracic Oncology · 1
PDF
[Dermatomyositis as a paraneoplastic first symptom of ovarian cancer].
2013 · Birgitte Bjørnhart, Younes Yazdanfard, et al. · PubMed · 1
Patient characteristics and quality of life in relation to place of death in lung cancer patients treated with immunotherapy
2026 · Amalie Rasmussen, Lotte Holm Land, et al. · Palliative & Supportive Care
PDF
5-Year survival in Danish patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy
2023 · Bjørnhart, Birgitte, Mouritzen, Mette Thune, et al. · Figshare
The impact of age and comorbidity on effect of treatment, adverse effects, and quality of life in Danish lung cancer patients receiving immunotherapy
2022 · Bjørnhart, Birgitte · University of Southern Denmark Research Portal (University of Southern Denmark)
1114P Long-term outcome in Danish real-life patients with advanced non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors
2022 · B. Bjornhart, M. Mouritzen, et al. · Annals of Oncology
MO-0388 Outcome of immunotherapy in non-small cell lung cancer patients with brain metastasis (NCT03870464)
2022 · B. Bjørnhart, K. Holmskov Hansen, et al. · Radiotherapy and Oncology
1289P Intracranial response (ICR) following immunotherapy in non-small cell lung cancer (NSCLC) patients with untreated brain metastasis (BM)
2021 · B. Bjoernhart, K.H. Hansen, et al. · Annals of Oncology
54P Impact of comorbidity and venous thromboembolism on outcome in real-life non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibition (ICI)
2020 · B. Bjoernhart, C. Kristiansen, et al. · Annals of Oncology
EP1.04-22 Efficacy and Safety of Immune Checkpoint Inhibitors in a Danish Real Life Non-Small Cell Lung Cancer Population
2019 · B. Bjørnhart, K. Hansen, et al. · Journal of Thoracic Oncology
Works count: 32
Citation count: 204
H-index: 9
I10-index: 8
Year
Topic
Type